Ionis Pharmaceuticals faces shareholder probe after trial collapse

The investigation, launched by the shareholders' rights firm Hagens Berman, seeks to determine if Ionis misled investors regarding the design and data of its Phase 3 CARDIO-TTRansform study. While management had recently described the trial as the largest of its kind and assured the public that execution was proceeding well, the final results indicated that the drug failed its primary efficacy endpoint. The market reaction was immediate, erasing more than $3.3 billion in market capitalization.

Analysts have pointed to a critical oversight regarding the study's participant profile: over 80 percent of those enrolled were already taking stabilizer treatments. Hagens Berman partner Reed Kathrein stated that the firm is examining when management became aware of these design flaws and whether they maintained sufficient transparency with the market. The probe now invites investors who suffered substantial losses to come forward, while also encouraging whistleblowers with non-public information to assist in the potential legal action.